Cargando…
A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk irrespective of conventional risk factors. The role of gut-liver interaction is implicated in its development. We investigated the effects of VSL#3(®) probiotic supplementation on biomarkers of car...
Autores principales: | Chong, Pui Lin, Laight, David, Aspinall, Richard J., Higginson, Antony, Cummings, Michael H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015038/ https://www.ncbi.nlm.nih.gov/pubmed/33794784 http://dx.doi.org/10.1186/s12876-021-01660-5 |
Ejemplares similares
-
Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018) -
Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Chong, Clara Yieh Lin, et al.
Publicado: (2020) -
Correction: Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018) -
Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
por: Cheng, Fang-Shu, et al.
Publicado: (2020) -
Probiotic Therapy With VSL#3(®) in Patients With NAFLD: A Randomized Clinical Trial
por: Derosa, Giuseppe, et al.
Publicado: (2022)